High-Sensitivity c-reactive protein is associated with incident type 2 diabetes among African Americans: The Jackson heart study

Diabetes Care

Volumn 38, Issue 9, 2015, Pages 1694-1700

  Effoe, Valery S ^a   Correa, Adolfo ^b   Chen, Haiying ^a   Lacy, Mary E ^c   Bertoni, Alain G ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; AFRICAN AMERICAN; ARTICLE; BODY MASS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; EPIDEMIOLOGY; ETHNOLOGY; HYPERTENSION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; AFRICAN AMERICANS; BIOMARKERS; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MALE; MIDDLE AGED; UNITED STATES; WAIST CIRCUMFERENCE;

EID: 84962459993     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0221     Document Type: Article

References (30)

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA, U.S. Department of Health and Human Services, 2014.
2. Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: The Cardiovascular Health Study. Diabetes 2001; 50:2384-2389.
3. Dehghan A, Kardys I, de Maat MP, et al. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 2007;56:872-878.
4. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM; Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: The insulin resistance atherosclerosis study. Diabetes 2002; 51:1131-1137.
5. Freeman DJ, Norrie J, Caslake MJ, et al.; West of Scotland Coronary Prevention Study. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51:1596-1600.
6. Han TS, Sattar N, Williams K, Gonzalez- Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002;25:2016-2021.
7. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004;53: 693-700.
8. Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N. Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care 2003;26: 2754-2757.
9. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-334.
10. Thorand B, Löwel H, Schneider A, et al. Creactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 2003;163:93-99.
11. Duncan BB, Schmidt MI, Pankow JS, et al.; Atherosclerosis Risk in Communities Study. Low-grade systemic inflammation and the development of type 2 diabetes: The atherosclerosis risk in communities study. Diabetes 2003;52: 1799-1805.
12. Negi SI, Pankow JS, Fernstrom K, et al. Racial differences in association of elevated interleukin- 18 levels with type 2 diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care 2012;35:1513-1518.
13. Bertoni AG, Burke GL, Owusu JA, et al. Inflammation and the incidence of type 2 diabetes: The Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2010;33:804-810.
14. Fuqua SR, Wyatt SB, Andrew ME, et al. Recruiting African-American research participation in the Jackson Heart Study: methods, response rates, and sample description. Ethn Dis 2005;15(4 Suppl.6):S6-18-S6-29.
15. Taylor HA Jr, Wilson JG, Jones DW, et al. Toward resolution of cardiovascular health disparities in African Americans: design and methods of the Jackson Heart Study. Ethn Dis 2005; 15(4 Suppl.6):S6-4-S6-17.
16. CarpenterMA, Crow R, Steffes M, et al. Laboratory, reading center, and coordinating center data management methods in the Jackson Heart Study. Am J Med Sci 2004;328:131-144.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
18. Fox ER, Benjamin EJ, Sarpong DF, et al. Epidemiology, heritability, and genetic linkage of C-reactive protein in African Americans (from the Jackson Heart Study). Am J Cardiol 2008; 102:835-841.
19. Law CG, Brookmeyer R. Effects of mid-point imputation on the analysis of doubly censored data. Stat Med 1992;11:1569-1578.
20. Lindsey JC, Ryan LM. Tutorial in biostatistics methods for interval-censored data. Stat Med 1998;17:219-238.
21. Freitag MH, Peila R, Masaki K, et al. Midlife pulse pressure and incidence of dementia: The Honolulu-Asia Aging Study. Stroke 2006;37: 33-37.
22. Helmer C, Joly P, Letenneur L, Commenges D, Dartigues JF. Mortality with dementia: results from a French prospective community-based cohort. Am J Epidemiol 2001;154:642-648.
23. Ridker PM, Cannon CP, Morrow D, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352: 20-28.
24. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001; 286:64-70.
25. Fukuchi Y, Miura Y, Nabeno Y, Kato Y, Osawa T, Naito M. Immunohistochemical detection of oxidative stress biomarkers, dityrosine and N(epsilon)-(hexanoyl)lysine, and C-reactive protein in rabbit atherosclerotic lesions. J Atheroscler Thromb 2008;15:185-192.
26. Jarva H, Jokiranta TS, Hellwage J, Zipfel PF, Meri S. Regulation of complement activation by C-reactive protein: Targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol 1999;163:3957- 3962.
27. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002;106:1439-1441.
28. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102: 2165-2168.
29. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated Creactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000;102:1000- 1006.
30. Song MJ, Kim KH, Yoon JM, Kim JB. Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun 2006;346:739-745.